Compare TREE & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | TREE | CTNM |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.5M | 550.7M |
| IPO Year | 2008 | 2024 |
| Metric | TREE | CTNM |
|---|---|---|
| Price | $26.05 | $13.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $71.25 | $19.00 |
| AVG Volume (30 Days) | 386.4K | ★ 431.9K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 443.31 | 0.46 |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $1,117,324,000.00 | N/A |
| Revenue This Year | $19.03 | N/A |
| Revenue Next Year | $7.07 | N/A |
| P/E Ratio | $14.19 | ★ N/A |
| Revenue Growth | ★ 24.12 | N/A |
| 52 Week Low | $25.56 | $8.60 |
| 52 Week High | $71.17 | $17.79 |
| Indicator | TREE | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 34.75 | 38.32 |
| Support Level | N/A | $13.65 |
| Resistance Level | $39.74 | $15.36 |
| Average True Range (ATR) | 1.09 | 0.86 |
| MACD | 0.19 | -0.30 |
| Stochastic Oscillator | 10.76 | 17.66 |
LendingTree Inc. is a U.S.-based company that mainly operates an online loan marketplace. The company offers online tools and resources to help consumers find loans or other credit-based products, including mortgage loans, reverse mortgages, home equity loans, personal loans, auto loans, credit cards, student loans, small business loans, and various related products. It provides consumers with direct access to a wide array of lenders. The company has three reportable segments: Home, Consumer, and Insurance. It generates match fees by connecting consumers with lenders and closing fees from lenders when a transaction is finalized. The company conducts business solely in the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.